高截留量血液透析与常规血液透析对骨髓瘤管型肾病患者透析依赖性的影响:一项随机临床试验
该多中心随机临床试验纳入98例活检证实的骨髓瘤管型肾病需透析患者,随机接受高截留量透析器(46例)或常规高通量透析器(48例)进行强化透析(10天内8次、每次5小时),所有患者均接受硼替佐米和地塞米松化疗。主要终点3个月透析依赖性率:高截留量组41.3% vs 常规组33.3%,组间差异8.0%(95%CI -12.0%至27.9%,P=0.42),无统计学显著差异;6个月为56.5% vs 35.4%(差异21.1%,95%CI 0.9%至41.3%,P=0.04);12个月为60.9% vs 37.5%(差异23.4%,95%CI 3.2%至43.5%,P=0.02)。透析相关不良事件发生率43% vs 39%,化疗相关严重不良事件39% vs 37%,12个月死亡9例 vs 10例。作者认为研究可能把握度不足,未能识别早期临床重要差异。
要点
- 在硼替佐米为基础化疗的骨髓瘤管型肾病患者中,高截留量透析对比常规高通量透析的3个月透析依赖性率无统计学显著差异(41.3% vs 33.3%,P=0.42)。
- 6个月透析依赖性率:高截留量组56.5% vs 常规组35.4%,组间差异21.1%(95%CI 0.9%至41.3%,P=0.04)。
- 12个月透析依赖性率:高截留量组60.9% vs 常规组37.5%,组间差异23.4%(95%CI 3.2%至43.5%,P=0.02)。
- 透析相关不良事件发生率:高截留量组43% vs 常规组39%;化疗相关严重不良事件:39% vs 37%;12个月死亡分别为9例和10例。
- 作者认为该研究可能把握度不足,未能识别早期临床重要差异。
适用人群与场景
- 新诊断的多发性骨髓瘤合并活检证实的管型肾病、需要血液透析的患者。
- 年龄中位数68.8岁(四分位距61.2-75.3岁),女性占45%。
处置流程与药物剂量
- 所有患者接受相同的硼替佐米和地塞米松化疗方案。
- 强化血液透析:10天内进行8次、每次5小时的透析 sessions。
- 高截留量透析器(膜孔很大,对免疫球蛋白轻链通透性高)或常规高通量透析器(膜孔小,通透性较低)。
研究设计与关键结果
- 多中心随机临床试验,98例随机化,94例(96%)纳入改良意向性分析;在法国48个中心进行,2011年7月至2016年6月,末次随访日期2016年6月29日。
- 主要终点3个月透析依赖性率:高截留量组41.3%(n=19) vs 常规组33.3%(n=16),组间差异8.0%(95%CI -12.0%至27.9%),P=0.42。
- 6个月透析依赖性率:高截留量组56.5%(n=26) vs 常规组35.4%(n=17),组间差异21.1%(95%CI 0.9%至41.3%),P=0.04。
- 12个月透析依赖性率:高截留量组60.9%(n=28) vs 常规组37.5%(n=18),组间差异23.4%(95%CI 3.2%至43.5%),P=0.02。
- 透析相关不良事件发生率:高截留量组43% vs 常规组39%;化疗相关严重不良事件:39% vs 37%;12个月死亡:高截留量组9例 vs 常规组10例。
证据类型、等级与局限
- 随机临床试验;原文未报告证据等级。
- 局限:作者指出研究可能把握度不足,未能识别早期临床重要差异。
对床旁实践的改变
- 在硼替佐米为基础化疗的骨髓瘤管型肾病患者中,高截留量透析对比常规高通量透析未能在3个月时显著提高透析依赖性率。
- 6个月和12个月时高截留量透析组的透析依赖性率显著高于常规高通量透析组,但作者认为该研究可能把握度不足,未能识别早期临床重要差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cast nephropathy is the main cause of acute kidney injury in multiple myeloma and persistent reduction in kidney function strongly affects prognosis. Strategies to rapidly remove nephrotoxic serum-free light chains combined with novel antimyeloma agents have not been evaluated prospectively.
OBJECTIVE: To compare the hemodialysis independence rate among patients newly diagnosed with myeloma cast nephropathy treated with hemodialysis using a high-cutoff dialyzer (with very large membrane pores and high permeability to immunoglobulin light chains) or a conventional high-flux dialyzer (with small pores and lower permeability).
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial involving 98 patients with biopsy-proven myeloma cast nephropathy requiring hemodialysis treated at 48 French centers between July 2011 and June 2016; the final date of follow-up was June 29, 2016.
INTERVENTIONS: Intensive hemodialysis (eight 5-hour sessions over 10 days) with either a high-cutoff dialyzer (46 patients) or a conventional high-flux dialyzer (48 patients). All patients received the same chemotherapy regimen of bortezomib and dexamethasone.
MAIN OUTCOMES AND MEASURES: Primary end point was hemodialysis independence at 3 months; secondary end points: hemodialysis independence rates at 6 and 12 months, hemodialysis- and chemotherapy-related adverse events, and death.
RESULTS: Among 98 randomized patients, 94 (96%) (median age, 68.8 years [interquartile range, 61.2-75.3 years]; 45% women) were included in the modified intent-to-treat analysis. The hemodialysis independence rate at 3 months was 41.3% (n = 19) in the high-cutoff hemodialysis group vs 33.3% (n = 16) in the conventional hemodialysis group (between-group difference, 8.0% [95% CI, -12.0% to 27.9%], P = .42); at 6 months, the rate was 56.5% (n = 26) vs 35.4% (n = 17), respectively (between-group difference, 21.1% [95% CI, 0.9% to 41.3%], P = .04); and at 12 months, the rate was 60.9% (n = 28) vs 37.5% (n = 18) (between-group difference, 23.4% [95% CI, 3.2% to 43.5%], P = .02). The incidence of hemodialysis-related adverse events was 43% in the high-cutoff hemodialysis group vs 39% in the conventional hemodialysis group; chemotherapy-related serious adverse events, 39% vs 37%, respectively; and at 12 months, 9 patients vs 10 patients died.
CONCLUSIONS AND RELEVANCE: Among patients with myeloma cast nephropathy treated with a bortezomib-based chemotherapy regimen, the use of high-cutoff hemodialysis compared with conventional hemodialysis did not result in a statistically significant difference in hemodialysis independence at 3 months. However, the study may have been underpowered to identify an early clinically important difference.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01208818.
参考来源
- Bridoux F, Carron PL, Pegourie B, et al. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial. JAMA. 2017. PMID: 29209721. doi:10.1001/jama.2017.17924
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。